Life Sciences & Medicine Active Updated Nov 22, 2026

Drugs finally grip the RAS cancer switch

Where it stands as of Nov 22, 2026

RAS-targeting drugs are now shrinking pancreatic and lung tumors in early trials. In 61 untreated metastatic pancreatic cancer patients, daraxonrasib plus chemotherapy shrank or cleared tumors in 60.7%, and the median time before tumors returned was 12.8 months, against five to six months typical with chemotherapy alone. The ERAS-0015 results come from a phase I trial with about four months of follow-up, and whether any of this extends survival is not yet known.

The story so far

  1. Nov 22, 2026 Latest

    At the EORTC-NCI-AACR symposium in Barcelona, the AURORAS-1 phase I trial of the pan-RAS molecular glue ERAS-0015 reported tumors shrinking considerably in 44% of 83 pancreatic cancer patients and 60% of 37 lung cancer patients who had already tried other treatments. A second trial gave daraxonrasib plus chemotherapy to 61 untreated metastatic pancreatic cancer patients, and tumors shrank or disappeared in 60.7%, with a median 12.8 months before progression.

    Today Got Better

This story moves with the morning letter.

When this question gets a new answer, the page above changes the same morning. Each morning's letter brings the day's progress in science, medicine and beyond. Free, every day.